Prevention of lysosomal storage disorders in Israel

Molecular Genetics and Metabolism

Volumn 90, Issue 4, 2007, Pages 353-357

  Bach, Gideon ^a   Zeigler, Marsha ^a   Zlotogora, Joel ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MINISTRY OF HEALTH   (Israel)

Author keywords

Lysosomal storage disorders; Population screening; Prevention program

Indexed keywords

CLINICAL GENETICS; CONSANGUINITY; ETHNIC GROUP; FAMILY PLANNING; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH CARE NEED; HEALTH PROGRAM; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; ISRAEL; LYSOSOME STORAGE DISEASE; MARRIAGE; MASS SCREENING; MEDICAL EXAMINATION; MEDICAL SPECIALIST; NON PROFIT ORGANIZATION; PRENATAL DIAGNOSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGENY; REVIEW;

GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; ISRAEL; LYSOSOMAL STORAGE DISEASES;

EID: 33947573900     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.11.001     Document Type: Review

References (38)

1. Futerman A.H. Lysosomal storage disorders: pathological mechanisms and therapeutic options. Med. Sci. 21 (2005) 16-19
2. Reuser A.J., and Drost M.R. Lysosomal dysfuction, cellular pathology and clinical symptoms: basic principals. Acta Paediatr. 95 (2006) 77-82
3. Saudubray J.M. Status of lysosomal diseases among metabolic diseases. Rev. Med. Int. 27 (2006) 511-513
4. Gieselmann V. Reversibility of cellular and organ pathology in enzyme replacement trials in animal models of lysosomal storage disorders. Acta Paediatr. 95 (2006) 93-99
5. Sawkar A.R., D'Haeze W., and Kelly J.W. Therapeutic strategies to ameliorate lysosomal storage disorders-A focus on Gaucher disease. Cell. Mol. Life Sci. 63 (2006) 1179-1192
6. Brady R.O. Enzyme replacement for lysosomal diseases. Annu. Rev. Med. 57 (2006) 283-296
7. Conway J., Dyack S., Crooks B.N., and Fernandez C.V. Mixed donor and low iduronidase expression may be adequate for neurodevelopmental protection in Hurler syndrome. J. Pediatr. 147 (2005) 106-108
8. Escolar M.L., Poe M.D., Provenzale J.M., Richards K.C., Allison J., Wood S., Wenger D.A., Pietryga D., Wall D., Champayne M., Moore R., Krivit W., and Kurtzberg J. Transplantation of umbilical cord blood in babies with infantile Krabbe disease. N. Engl. J. Med. 352 (2005) 2069-2081
9. Sands M.S., and Davidson B.L. Gene therapy for lysosomal storage disease. Mol. Ther. 13 (2006) 839-849
10. Biffi A., and Naldini L. Gene therapy of storage disorders by retroviral vectors. Hum. Gene Ther. 16 (2005) 1133-1142
11. Lachmann R.H. Miglustat substrate reduction therapy for glycosphingolipid lysosomal storage disorders. Drugs Today 42 (2006) 29-38
12. Platt F.M., Jeyakumar M., Andersson U., Dwek R.A., and Butters T.D. New development in treating glycosphingolipid storage diseases. Adv. Exp. Med. Biol. 564 (2005) 117-126
13. Wraith J.E. Limitations of enzyme replacement therapy: current and future. J. Inherit. Metab. Dis. 29 (2006) 442-447
14. Modell B. Delivering genetic screening to the community. Ann. Med. 29 (1997) 591-599
15. Vallance H., and Ford J. Carrier testing for autosomal recessive disdorders. Crit. Rev. Clin. Lab. Sci. 40 (2003) 473-497
16. Kaback M.M., Nathan T.J., and Greenwald S. Tay Sachs disease: heterozygote screening and prenatal disagnosis, U.S. and world perspective. In: Kabake M.M. (Ed). Tay Sachs screening and prevention (1977), Alan R. Liss Inc., New York 13-36
17. Kaback M.M. Screening and prevention in Tay Sachs disease: origins, update and impact. Adv. Genet. 44 (2001) 253-265
18. Statistical Abstracts of Israel, 2005. Central Bureau of Statistics, Israel Government, 2006.
19. Bromiker R., Glam-Baruch M., Gofin R., Hammerman C., and Amitai Y. Association of parental consanguinity with congenital malformations among Arab new born in Jerusalem. Clin. Genet. 66 (2004) 63-64
20. Jaber L., Merlob P., Bu X., Rotter J.I., and Shohat M. Marked parental consanguinity as a cause for increased major malformations in an Israeli Arab community. Am. J. Med. Genet. 44 (1992) 1-6
21. Vardi-Saliternik R., Friedlender Y., and Cohen T. Consanguinity in a population sample of Israeli Muslim Arabs, Christian Arabs and Druze. Ann. Hum. Biol. 29 (2002) 422-431
22. Wilson J.M.G., and Janger G. Principles and practice of screening for disease (1968), WHO, Geneva
23. Godard B., Ten Kate L., Evers-Kiebooms G., and Ayme S. Population genetic screening programmes: principles, techniques, practices and policies. Eur. J. Hum. Genet. 11 (2003) S49-S87
24. Broide E., Zeigler M., Ekstein J., and Bach G. Screening for Tay Sachs disease in the ultra-orthodox Ashkeanzi Jewish Community in Israel. Am. J. Med. Genet. 47 (1993) 213-215
25. Ekstein J., and Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay Sachs disease. Adv. Genet. 44 (2001) 297-310
26. Zlotogora J., Bach G., and Munnich A. Molecular basis of Mendelian disorders among Jews. Mol. Genet. Metab. 69 (2000) 169-180
27. Strom C.M., Crossley B., Redman J.B., Quan F., Buller A., McGinniss M.J., and Sun W. Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet. Med. 6 (2004) 145-152
28. Padeh B. A screening program for Tay Sachs Disease in Israel. Isr. J. Med. Sci. 9 (1973) 1330-1334
29. Bach G., Tomczak J., Risch N., and Ekstein J. Tay Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am. J. Med. Genet. 99 (2001) 70-75
30. Zlotogora J., and Leventhal A. Screening for genetic disorders among Jews: how should the Tay Sachs screening program be continued. Isr. J. Med. Assoc. J. 2 (2000) 665-667
31. Risch N., Tang H., Katzenstein H., and Ekstein J. Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am. J. Hum. Genet. 72 (2003) 812-822
32. Leib J.R., Gollust S.E., Hull S.C., and Willford B.S. Carrier screening panels for Ashkenazi Jews: is more better?. Genet. Med. 7 (2005) 185-190
33. Beutler E., and Grabowsky G.A. Gaucher disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease. eigth ed. (2001), McGrow Hill, NY 3635-3668
34. Zlotogora J., Bach G., Barak Y., and Elian E. Metachromatic leukodystrophy in the Habbanite Jews: high frequency in a genetic isolate and screening for heterozytoes. Am. J. Hum. Genet. 32 (1980) 663-669
35. Raas-Rothschild A., Bargal R., Goldman O., Ben-Asher E., Groener J.E.M., Toutian A., Stemmer E., Ben-Neriah Z., Flusser H., Beemer F.A., Penttinen M., Olender T., Rein A.J.J.T., Bach G., and Zeigler M. Genomic organization of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis type III. J. Med. Genet. 41 (2004) 52-57
36. Meikle P.J., Grasby D.J., Dean C.J., Land D.L., Bockmann M., Whittle A.M., Fietz M.J., Simonsen H., Fuller M., Brooks D.A., and Hopwood J.J. Newborn screening for lysosomal disorders. Mol. Genet. Metab. 88 (2006) 307-314
37. Gelb M.H., Turecek F., Scott C.R., and Chamole N.A. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for newborn screening of lysosomal storage disorders. J. Inherit. Metab. Dis. 29 (2006) 397-404
38. Fletcher J.M. Screening for lysosomal storage disorders-A clinical perspective. J. Inherit. Metab. Dis. 29 (2006) 405-408